{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T01:45:37Z","timestamp":1783993537670,"version":"3.55.0"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Scientific Research Special Fund Project of Zhejiang Association of Rehabilitation Medicine","award":["ZKKY2024002"],"award-info":[{"award-number":["ZKKY2024002"]}]},{"name":"Scientific Research Special Fund Project of Zhejiang Association of Rehabilitation Medicine","award":["ZKKY2024002"],"award-info":[{"award-number":["ZKKY2024002"]}]},{"name":"Scientific Research Special Fund Project of Zhejiang Association of Rehabilitation Medicine","award":["ZKKY2024002"],"award-info":[{"award-number":["ZKKY2024002"]}]},{"name":"Scientific Research Special Fund Project of Zhejiang Association of Rehabilitation Medicine","award":["ZKKY2024002"],"award-info":[{"award-number":["ZKKY2024002"]}]},{"name":"Scientific Research Special Fund Project of Zhejiang Association of Rehabilitation Medicine","award":["ZKKY2024002"],"award-info":[{"award-number":["ZKKY2024002"]}]},{"name":"Scientific Research Special Fund Project of Zhejiang Association of Rehabilitation Medicine","award":["ZKKY2024002"],"award-info":[{"award-number":["ZKKY2024002"]}]},{"name":"Scientific Research Special Fund Project of Zhejiang Association of Rehabilitation Medicine","award":["ZKKY2024002"],"award-info":[{"award-number":["ZKKY2024002"]}]},{"name":"Scientific Research Special Fund Project of Zhejiang Association of Rehabilitation Medicine","award":["ZKKY2024002"],"award-info":[{"award-number":["ZKKY2024002"]}]},{"name":"Scientific Research Special Fund Project of Zhejiang Association of Rehabilitation Medicine","award":["ZKKY2024002"],"award-info":[{"award-number":["ZKKY2024002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-026-05058-6","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:14:10Z","timestamp":1780575250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mesenchymal stromal cell therapy for systemic lupus erythematosus: mechanisms, clinical translation, and future directions"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9545-0665","authenticated-orcid":false,"given":"Shuaijie","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2635-3722","authenticated-orcid":false,"given":"Shiyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0036-7430","authenticated-orcid":false,"given":"Yixin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruitian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7469-1280","authenticated-orcid":false,"given":"Yixuan Wang","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5443-3675","authenticated-orcid":false,"given":"Zhenhua","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"11","key":"5058_CR1","doi-asserted-by":"publisher","first-page":"Itc81","DOI":"10.7326\/aitc202006020","volume":"172","author":"M Kiriakidou","year":"2020","unstructured":"Kiriakidou M, Ching CL. Systemic Lupus Erythematosus. Ann Intern Med. 2020;172(11):Itc81\u201396. https:\/\/doi.org\/10.7326\/aitc202006020.","journal-title":"Ann Intern Med"},{"key":"5058_CR2","doi-asserted-by":"publisher","first-page":"1395609","DOI":"10.3389\/fimmu.2024.1395609","volume":"15","author":"L Meng","year":"2024","unstructured":"Meng L, Wang Y, Yang Z, Lin S, Wang Y, Chen H, et al. Ocular fundus changes and association with systemic conditions in systemic lupus erythematosus. Front Immunol. 2024;15:1395609. https:\/\/doi.org\/10.3389\/fimmu.2024.1395609.","journal-title":"Front Immunol"},{"issue":"6","key":"5058_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nm.2752","volume":"18","author":"Z Liu","year":"2012","unstructured":"Liu Z, Davidson A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med. 2012;18(6):871\u201382. https:\/\/doi.org\/10.1038\/nm.2752.","journal-title":"Nat Med"},{"key":"5058_CR4","doi-asserted-by":"publisher","unstructured":"Shiozawa S. Pathogenesis of Autoimmunity\/Systemic Lupus Erythematosus (SLE). Cells. 2025. https:\/\/doi.org\/10.3390\/cells14141080.","DOI":"10.3390\/cells14141080"},{"key":"5058_CR5","doi-asserted-by":"publisher","first-page":"e073980","DOI":"10.1136\/bmj-2022-073980","volume":"383","author":"EF Morand","year":"2023","unstructured":"Morand EF, Fernandez-Ruiz R, Blazer A, Niewold TB. Advances in the management of systemic lupus erythematosus. BMJ. 2023;383:e073980. https:\/\/doi.org\/10.1136\/bmj-2022-073980.","journal-title":"BMJ"},{"issue":"1","key":"5058_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","volume":"10","author":"X Dai","year":"2025","unstructured":"Dai X, Fan Y, Zhao X. Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics. Signal Transduct Target Ther. 2025;10(1):102. https:\/\/doi.org\/10.1038\/s41392-025-02168-0.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"5058_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/annrheumdis-2018-214502","volume":"78","author":"D Jesus","year":"2019","unstructured":"Jesus D, Matos A, Henriques C, Zen M, Larosa M, Iaccarino L, et al. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis. 2019;78(3):365\u201371. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214502.","journal-title":"Ann Rheum Dis"},{"key":"5058_CR8","doi-asserted-by":"publisher","first-page":"1602235","DOI":"10.3389\/fimmu.2025.1602235","volume":"16","author":"DN Habiballah","year":"2025","unstructured":"Habiballah DN, Li F, Jiang L. Immune metabolic restoration in systemic lupus erythematosus: the impact of gut microbiota, probiotics, and nutritional synergy. Front Immunol. 2025;16:1602235. https:\/\/doi.org\/10.3389\/fimmu.2025.1602235.","journal-title":"Front Immunol"},{"issue":"11","key":"5058_CR9","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1177\/0961203317693096","volume":"26","author":"M Taraborelli","year":"2017","unstructured":"Taraborelli M, Cavazzana I, Martinazzi N, Lazzaroni MG, Fredi M, Andreoli L, et al. Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years. Lupus. 2017;26(11):1197\u2013204. https:\/\/doi.org\/10.1177\/0961203317693096.","journal-title":"Lupus"},{"key":"5058_CR10","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3389\/fimmu.2019.00772","volume":"10","author":"AA Herrada","year":"2019","unstructured":"Herrada AA, Escobedo N, Iruretagoyena M, Valenzuela RA, Burgos PI, Cuitino L, et al. Innate Immune Cells\u2019 Contribution to Systemic Lupus Erythematosus. Front Immunol. 2019;10:772. https:\/\/doi.org\/10.3389\/fimmu.2019.00772.","journal-title":"Front Immunol"},{"issue":"11","key":"5058_CR11","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","volume":"56","author":"F Rees","year":"2017","unstructured":"Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017;56(11):1945\u201361. https:\/\/doi.org\/10.1093\/rheumatology\/kex260.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"5058_CR12","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/bor.0000000000000480","volume":"30","author":"G Stojan","year":"2018","unstructured":"Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018;30(2):144\u201350. https:\/\/doi.org\/10.1097\/bor.0000000000000480.","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"5058_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m17-0102","volume":"167","author":"EY Yen","year":"2017","unstructured":"Yen EY, Shaheen M, Woo JMP, Mercer N, Li N, McCurdy DK, et al. 46-Year Trends in Systemic Lupus Erythematosus Mortality in the United States, 1968 to 2013: A Nationwide Population-Based Study. Ann Intern Med. 2017;167(11):777\u201385. https:\/\/doi.org\/10.7326\/m17-0102.","journal-title":"Ann Intern Med"},{"issue":"17","key":"5058_CR14","doi-asserted-by":"publisher","first-page":"e794","DOI":"10.1097\/md.0000000000000794","volume":"94","author":"Z Wang","year":"2015","unstructured":"Wang Z, Wang Y, Zhu R, Tian X, Xu D, Wang Q, et al. Long-term survival and death causes of systemic lupus erythematosus in China: a systemic review of observational studies. Med (Baltim). 2015;94(17):e794. https:\/\/doi.org\/10.1097\/md.0000000000000794.","journal-title":"Med (Baltim)"},{"issue":"8","key":"5058_CR15","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/art.21955","volume":"54","author":"S Bernatsky","year":"2006","unstructured":"Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550\u20137. https:\/\/doi.org\/10.1002\/art.21955.","journal-title":"Arthritis Rheum"},{"key":"5058_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejim.2023.02.004","volume":"112","author":"M Zen","year":"2023","unstructured":"Zen M, Salmaso L, Barbiellini Amidei C, Fedeli U, Bellio S, Iaccarino L, et al. Mortality and causes of death in systemic lupus erythematosus over the last decade: Data from a large population-based study. Eur J Intern Med. 2023;112:45\u201351. https:\/\/doi.org\/10.1016\/j.ejim.2023.02.004.","journal-title":"Eur J Intern Med"},{"issue":"7","key":"5058_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/0961203315627202","volume":"25","author":"YH Lee","year":"2016","unstructured":"Lee YH, Choi SJ, Ji JD, Song GG. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016;25(7):727\u201334. https:\/\/doi.org\/10.1177\/0961203315627202.","journal-title":"Lupus"},{"key":"5058_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1146\/annurev-med-043021-032611","volume":"74","author":"S Lazar","year":"2023","unstructured":"Lazar S, Kahlenberg JM. Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches. Annu Rev Med. 2023;74:339\u201352. https:\/\/doi.org\/10.1146\/annurev-med-043021-032611.","journal-title":"Annu Rev Med"},{"key":"5058_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/tcrm.S252592","volume":"17","author":"A Bag-Ozbek","year":"2021","unstructured":"Bag-Ozbek A, Hui-Yuen JS. Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021;17:39\u201354. https:\/\/doi.org\/10.2147\/tcrm.S252592.","journal-title":"Ther Clin Risk Manag"},{"key":"5058_CR20","doi-asserted-by":"publisher","first-page":"8142368","DOI":"10.1155\/2019\/8142368","volume":"2019","author":"D Samotij","year":"2019","unstructured":"Samotij D, Reich A. Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review. Biomed Res Int. 2019;2019:8142368. https:\/\/doi.org\/10.1155\/2019\/8142368.","journal-title":"Biomed Res Int"},{"issue":"6","key":"5058_CR21","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.autrev.2017.04.011","volume":"16","author":"JF Kleinmann","year":"2017","unstructured":"Kleinmann JF, Tubach F, Le Guern V, Mathian A, Richez C, Saadoun D, et al. International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmun Rev. 2017;16(6):650\u20137. https:\/\/doi.org\/10.1016\/j.autrev.2017.04.011.","journal-title":"Autoimmun Rev"},{"issue":"11","key":"5058_CR22","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","volume":"75","author":"M Khamashta","year":"2016","unstructured":"Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, et al. Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(11):1909\u201316. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208562.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5058_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.semarthrit.2018.01.001","volume":"48","author":"S Oon","year":"2018","unstructured":"Oon S, Huq M, Godfrey T, Nikpour M. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus. Semin Arthritis Rheum. 2018;48(2):221\u201339. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.01.001.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"5058_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.molmed.2020.09.009","volume":"27","author":"ME Allen","year":"2021","unstructured":"Allen ME, Rus V, Szeto GL. Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies. Trends Mol Med. 2021;27(2):152\u201371. https:\/\/doi.org\/10.1016\/j.molmed.2020.09.009.","journal-title":"Trends Mol Med"},{"issue":"10188","key":"5058_CR25","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/s0140-6736(19)30237-5","volume":"393","author":"L Durcan","year":"2019","unstructured":"Durcan L, O\u2019Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332\u201343. https:\/\/doi.org\/10.1016\/s0140-6736(19)30237-5.","journal-title":"Lancet"},{"issue":"5","key":"5058_CR26","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1021\/acs.molpharmaceut.7b01146","volume":"15","author":"S Mai","year":"2018","unstructured":"Mai S, Zou L, Tian X, Liao X, Luan Y, Han X, et al. Double-Edged Effect of Hydroxychloroquine on Human Umbilical Cord-Derived Mesenchymal Stem Cells Treating Lupus Nephritis in MRL\/lpr Mice. Mol Pharm. 2018;15(5):1800\u201313. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b01146.","journal-title":"Mol Pharm"},{"key":"5058_CR27","doi-asserted-by":"publisher","first-page":"103291","DOI":"10.1016\/j.jaut.2024.103291","volume":"148","author":"L Zeng","year":"2024","unstructured":"Zeng L, Yang K, Wu Y, Yu G, Yan Y, Hao M, et al. Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases. J Autoimmun. 2024;148:103291. https:\/\/doi.org\/10.1016\/j.jaut.2024.103291.","journal-title":"J Autoimmun"},{"issue":"1","key":"5058_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0307-742X(21)00211-3","volume":"8","author":"JV Jones","year":"1982","unstructured":"Jones JV. Plasmapheresis in SLE. Clin Rheum Dis. 1982;8(1):243\u201360.","journal-title":"Clin Rheum Dis"},{"issue":"2","key":"5058_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semarthrit.2006.04.008","volume":"36","author":"CC Mok","year":"2006","unstructured":"Mok CC. Therapeutic options for resistant lupus nephritis. Semin Arthritis Rheum. 2006;36(2):71\u201381. https:\/\/doi.org\/10.1016\/j.semarthrit.2006.04.008.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"5058_CR30","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1002\/acr.22589","volume":"67","author":"C Muangchan","year":"2015","unstructured":"Muangchan C, van Vollenhoven RF, Bernatsky SR, Smith CD, Hudson M, Inan\u00e7 M, et al. Treatment Algorithms in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2015;67(9):1237\u201345. https:\/\/doi.org\/10.1002\/acr.22589.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"5058_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1365-2184.1970.tb00347.x","volume":"3","author":"AJ Friedenstein","year":"1970","unstructured":"Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970;3(4):393\u2013403. https:\/\/doi.org\/10.1111\/j.1365-2184.1970.tb00347.x.","journal-title":"Cell Tissue Kinet"},{"issue":"10","key":"5058_CR32","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1182\/blood-2007-02-069716","volume":"110","author":"AJ Nauta","year":"2007","unstructured":"Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110(10):3499\u2013506. https:\/\/doi.org\/10.1182\/blood-2007-02-069716.","journal-title":"Blood"},{"issue":"3","key":"5058_CR33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nbt.2816","volume":"32","author":"JA Ankrum","year":"2014","unstructured":"Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014;32(3):252\u201360. https:\/\/doi.org\/10.1038\/nbt.2816.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"5058_CR34","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/bmt.2017.1","volume":"52","author":"M Cetin","year":"2017","unstructured":"Cetin M, Akyol G, Gonen ZB, Keklik M, Zararsiz G, Unal A, et al. Additional infusions of mesenchymal stem cells improve response rate in multidrug-resistant GvHD patients. Bone Marrow Transpl. 2017;52(5):783\u20135. https:\/\/doi.org\/10.1038\/bmt.2017.1.","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"5058_CR35","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/stem.430","volume":"28","author":"JS Lee","year":"2010","unstructured":"Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010;28(6):1099\u2013106. https:\/\/doi.org\/10.1002\/stem.430.","journal-title":"Stem Cells"},{"issue":"22","key":"5058_CR36","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1001\/jama.2012.25321","volume":"308","author":"JM Hare","year":"2012","unstructured":"Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, et al. Comparison of allogeneic vs autologous bone marrow\u2013derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369\u201379. https:\/\/doi.org\/10.1001\/jama.2012.25321.","journal-title":"JAMA"},{"issue":"1","key":"5058_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/hep.29189","volume":"66","author":"BL Lin","year":"2017","unstructured":"Lin BL, Chen JF, Qiu WH, Wang KW, Xie DY, Chen XY, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial. Hepatology. 2017;66(1):209\u201319. https:\/\/doi.org\/10.1002\/hep.29189.","journal-title":"Hepatology"},{"key":"5058_CR38","doi-asserted-by":"publisher","first-page":"1616231","DOI":"10.3389\/fimmu.2025.1616231","volume":"16","author":"Y Chen","year":"2025","unstructured":"Chen Y, Li X, Zhang J, Peng J, Huang F, Bao J, et al. Global clinical trials on stem cell therapy for autoimmune diseases: trends and future directions. Front Immunol. 2025;16:1616231. https:\/\/doi.org\/10.3389\/fimmu.2025.1616231.","journal-title":"Front Immunol"},{"key":"5058_CR39","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/1471-2474-13-249","volume":"13","author":"Q Wang","year":"2012","unstructured":"Wang Q, Li X, Luo J, Zhang L, Ma L, Lv Z, et al. The allogeneic umbilical cord mesenchymal stem cells regulate the function of T helper 17 cells from patients with rheumatoid arthritis in an in vitro co-culture system. BMC Musculoskelet Disord. 2012;13:249. https:\/\/doi.org\/10.1186\/1471-2474-13-249.","journal-title":"BMC Musculoskelet Disord"},{"key":"5058_CR40","doi-asserted-by":"crossref","unstructured":"Beyer Nardi N, da Silva Meirelles L. Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol. 2006.174:249\u201382.","DOI":"10.1007\/3-540-31265-X_11"},{"key":"5058_CR41","doi-asserted-by":"publisher","first-page":"130763","DOI":"10.1155\/2013\/130763","volume":"2013","author":"A Sohni","year":"2013","unstructured":"Sohni A, Verfaillie CM. Mesenchymal stem cells migration homing and tracking. Stem Cells Int. 2013;2013:130763. https:\/\/doi.org\/10.1155\/2013\/130763.","journal-title":"Stem Cells Int"},{"issue":"25","key":"5058_CR42","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1182\/blood-2010-10-311464","volume":"118","author":"D Sarkar","year":"2011","unstructured":"Sarkar D, Spencer JA, Phillips JA, Zhao W, Schafer S, Spelke DP, et al. Engineered cell homing. Blood. 2011;118(25):e184\u201391. https:\/\/doi.org\/10.1182\/blood-2010-10-311464.","journal-title":"Blood"},{"issue":"6","key":"5058_CR43","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jbspin.2003.08.001","volume":"70","author":"C Jorgensen","year":"2003","unstructured":"Jorgensen C, Djouad F, Fritz V, Apparailly F, Plence P, No\u00ebl D. Mesenchymal stem cells and rheumatoid arthritis. Joint Bone Spine. 2003;70(6):483\u20135. https:\/\/doi.org\/10.1016\/j.jbspin.2003.08.001.","journal-title":"Joint Bone Spine"},{"issue":"3","key":"5058_CR44","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/01.Tp.0000045055.63901.A9","volume":"75","author":"WT Tse","year":"2003","unstructured":"Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75(3):389\u201397. https:\/\/doi.org\/10.1097\/01.Tp.0000045055.63901.A9.","journal-title":"Transplantation"},{"issue":"10","key":"5058_CR45","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1182\/blood.v99.10.3838","volume":"99","author":"M Di Nicola","year":"2002","unstructured":"Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99(10):3838\u201343. https:\/\/doi.org\/10.1182\/blood.v99.10.3838.","journal-title":"Blood"},{"issue":"9","key":"5058_CR46","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1182\/blood-2002-07-2104","volume":"101","author":"M Krampera","year":"2003","unstructured":"Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2003;101(9):3722\u20139. https:\/\/doi.org\/10.1182\/blood-2002-07-2104.","journal-title":"Blood"},{"issue":"2","key":"5058_CR47","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/stem.2254","volume":"34","author":"P Luz-Crawford","year":"2016","unstructured":"Luz-Crawford P, Djouad F, Toupet K, Bony C, Franquesa M, Hoogduijn MJ, et al. Mesenchymal Stem Cell-Derived Interleukin 1 Receptor Antagonist Promotes Macrophage Polarization and Inhibits B Cell Differentiation. Stem Cells. 2016;34(2):483\u201392. https:\/\/doi.org\/10.1002\/stem.2254.","journal-title":"Stem Cells"},{"issue":"4","key":"5058_CR48","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.bbrc.2014.07.001","volume":"450","author":"Y Liu","year":"2014","unstructured":"Liu Y, Yin Z, Zhang R, Yan K, Chen L, Chen F, et al. MSCs inhibit bone marrow-derived DC maturation and function through the release of TSG-6. Biochem Biophys Res Commun. 2014;450(4):1409\u201315. https:\/\/doi.org\/10.1016\/j.bbrc.2014.07.001.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"5058_CR49","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1182\/blood-2007-02-074997","volume":"111","author":"GM Spaggiari","year":"2008","unstructured":"Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008;111(3):1327\u201333. https:\/\/doi.org\/10.1182\/blood-2007-02-074997.","journal-title":"Blood"},{"issue":"2","key":"5058_CR50","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.3892\/mmr.2018.9181","volume":"18","author":"YB Yu","year":"2018","unstructured":"Yu YB, Song Y, Chen Y, Zhang F, Qi FZ. Differentiation of umbilical cord mesenchymal stem cells into hepatocytes in comparison with bone marrow mesenchymal stem cells. Mol Med Rep. 2018;18(2):2009\u201316. https:\/\/doi.org\/10.3892\/mmr.2018.9181.","journal-title":"Mol Med Rep"},{"issue":"6","key":"5058_CR51","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1177\/096120339700600613","volume":"6","author":"AM Marmont","year":"1997","unstructured":"Marmont AM, van Lint MT, Gualandi F, Bacigalupo A. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus. 1997;6(6):545\u20138. https:\/\/doi.org\/10.1177\/096120339700600613.","journal-title":"Lupus"},{"key":"5058_CR52","doi-asserted-by":"publisher","first-page":"100241","DOI":"10.1016\/j.jtauto.2024.100241","volume":"8","author":"M Zare Moghaddam","year":"2024","unstructured":"Zare Moghaddam M, Mousavi MJ, Ghotloo S. Stem cell-based therapy for systemic lupus erythematous. J Transl Autoimmun. 2024;8:100241. https:\/\/doi.org\/10.1016\/j.jtauto.2024.100241.","journal-title":"J Transl Autoimmun"},{"issue":"11","key":"5058_CR53","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1177\/0961203315583541","volume":"24","author":"Q Wang","year":"2015","unstructured":"Wang Q, Qian S, Li J, Che N, Gu L, Wang Q, et al. Combined transplantation of autologous hematopoietic stem cells and allogenic mesenchymal stem cells increases T regulatory cells in systemic lupus erythematosus with refractory lupus nephritis and leukopenia. Lupus. 2015;24(11):1221\u20136. https:\/\/doi.org\/10.1177\/0961203315583541.","journal-title":"Lupus"},{"issue":"12","key":"5058_CR54","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1136\/ard.2010.148049","volume":"70","author":"GG Illei","year":"2011","unstructured":"Illei GG, Cervera R, Burt RK, Doria A, Hiepe F, Jayne D, et al. Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. Ann Rheum Dis. 2011;70(12):2071\u20134. https:\/\/doi.org\/10.1136\/ard.2010.148049.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5058_CR55","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s13287-020-01837-x","volume":"11","author":"J Qi","year":"2020","unstructured":"Qi J, Tang X, Li W, Chen W, Yao G, Sun L. Mesenchymal stem cells inhibited the differentiation of MDSCs via COX2\/PGE2 in experimental sialadenitis. Stem Cell Res Ther. 2020;11(1):325. https:\/\/doi.org\/10.1186\/s13287-020-01837-x.","journal-title":"Stem Cell Res Ther"},{"key":"5058_CR56","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ebiom.2018.01.002","volume":"28","author":"DS Kim","year":"2018","unstructured":"Kim DS, Jang IK, Lee MW, Ko YJ, Lee DH, Lee JW, et al. Enhanced Immunosuppressive Properties of Human Mesenchymal Stem Cells Primed by Interferon-\u03b3. EBioMedicine. 2018;28:261\u201373. https:\/\/doi.org\/10.1016\/j.ebiom.2018.01.002.","journal-title":"EBioMedicine"},{"issue":"4","key":"5058_CR57","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315\u20137. https:\/\/doi.org\/10.1080\/14653240600855905.","journal-title":"Cytotherapy"},{"issue":"10","key":"5058_CR58","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jcyt.2019.08.002","volume":"21","author":"S Viswanathan","year":"2019","unstructured":"Viswanathan S, Shi Y, Galipeau J, Krampera M, Leblanc K, Martin I, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT\u00ae) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. 2019;21(10):1019\u201324. https:\/\/doi.org\/10.1016\/j.jcyt.2019.08.002.","journal-title":"Cytotherapy"},{"issue":"2","key":"5058_CR59","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jcyt.2024.10.008","volume":"27","author":"L Renesme","year":"2025","unstructured":"Renesme L, Cobey KD, Lalu MM, Bubela T, Chinnadurai R, De Vos J, et al. Delphi-driven consensus definition for mesenchymal stromal cells and clinical reporting guidelines for mesenchymal stromal cell-based therapeutics. Cytotherapy. 2025;27(2):146\u201368. https:\/\/doi.org\/10.1016\/j.jcyt.2024.10.008.","journal-title":"Cytotherapy"},{"issue":"4","key":"5058_CR60","doi-asserted-by":"publisher","first-page":"e42311","DOI":"10.1016\/j.heliyon.2025.e42311","volume":"11","author":"K Yan","year":"2025","unstructured":"Yan K, Ma F, Song X, Wang H, Liu P, Zhang J, et al. Unveiling distinctions between mesenchymal stromal cells and stem cells by single-cell transcriptomic analysis. Heliyon. 2025;11(4):e42311. https:\/\/doi.org\/10.1016\/j.heliyon.2025.e42311.","journal-title":"Heliyon"},{"issue":"1","key":"5058_CR61","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13287-022-02763-w","volume":"13","author":"R Vij","year":"2022","unstructured":"Vij R, Stebbings KA, Kim H, Park H, Chang D. Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I\/IIa, open-label, non-randomized pilot trial. Stem Cell Res Ther. 2022;13(1):88. https:\/\/doi.org\/10.1186\/s13287-022-02763-w.","journal-title":"Stem Cell Res Ther"},{"key":"5058_CR62","doi-asserted-by":"publisher","first-page":"156960","DOI":"10.1016\/j.cyto.2025.156960","volume":"191","author":"W Zou","year":"2025","unstructured":"Zou W, Zhang Z, Cao T, Li M. Mesenchymal stem cell transplantation ameliorates inflammation in spinal cord injury by inhibiting lactylation-related genes. Cytokine. 2025;191:156960. https:\/\/doi.org\/10.1016\/j.cyto.2025.156960.","journal-title":"Cytokine"},{"issue":"11","key":"5058_CR63","doi-asserted-by":"publisher","first-page":"9433","DOI":"10.1002\/jcb.27260","volume":"119","author":"S Nojehdehi","year":"2018","unstructured":"Nojehdehi S, Soudi S, Hesampour A, Rasouli S, Soleimani M, Hashemi SM. Immunomodulatory effects of mesenchymal stem cell-derived exosomes on experimental type-1 autoimmune diabetes. J Cell Biochem. 2018;119(11):9433\u201343. https:\/\/doi.org\/10.1002\/jcb.27260.","journal-title":"J Cell Biochem"},{"issue":"3","key":"5058_CR64","doi-asserted-by":"publisher","first-page":"100799","DOI":"10.1016\/j.ajps.2023.100799","volume":"18","author":"J Zeng","year":"2023","unstructured":"Zeng J, Sun P, Zhao Y, Fang X, Wu Z, Qi X. Bone mesenchymal stem cell-derived exosomes involved co-delivery and synergism effect with icariin via mussel-inspired multifunctional hydrogel for cartilage protection. Asian J Pharm Sci. 2023;18(3):100799. https:\/\/doi.org\/10.1016\/j.ajps.2023.100799.","journal-title":"Asian J Pharm Sci"},{"issue":"1","key":"5058_CR65","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41392-025-02320-w","volume":"10","author":"Y Liu","year":"2025","unstructured":"Liu Y, Liu Y, Hu J, Han J, Song L, Liu X, et al. Impact of allogeneic dental pulp stem cell injection on tissue regeneration in periodontitis: a multicenter randomized clinical trial. Signal Transduct Target Ther. 2025;10(1):239. https:\/\/doi.org\/10.1038\/s41392-025-02320-w.","journal-title":"Signal Transduct Target Ther"},{"key":"5058_CR66","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.2147\/dddt.S225613","volume":"13","author":"L Wang","year":"2019","unstructured":"Wang L, Huang S, Li S, Li M, Shi J, Bai W, et al. Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I\/II Study. Drug Des Devel Ther. 2019;13:4331\u201340. https:\/\/doi.org\/10.2147\/dddt.S225613.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"5058_CR67","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/s13287-024-04064-w","volume":"15","author":"G Lombardo","year":"2024","unstructured":"Lombardo G, Lechanteur C, Briquet A, Seidel L, Willems E, Servais S, et al. Co-infusion of mesenchymal stromal cells to prevent GVHD after allogeneic hematopoietic cell transplantation from HLA-mismatched unrelated donors after reduced-intensity conditioning: a double-blind randomized study and literature review. Stem Cell Res Ther. 2024;15(1):461. https:\/\/doi.org\/10.1186\/s13287-024-04064-w.","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"5058_CR68","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41419-020-2542-9","volume":"11","author":"Y Guo","year":"2020","unstructured":"Guo Y, Yu Y, Hu S, Chen Y, Shen Z. The therapeutic potential of mesenchymal stem cells for cardiovascular diseases. Cell Death Dis. 2020;11(5):349. https:\/\/doi.org\/10.1038\/s41419-020-2542-9.","journal-title":"Cell Death Dis"},{"key":"5058_CR69","doi-asserted-by":"publisher","first-page":"860083","DOI":"10.3389\/fneur.2022.860083","volume":"13","author":"XY Yao","year":"2022","unstructured":"Yao XY, Xie L, Cai Y, Zhang Y, Deng Y, Gao MC, et al. Human Umbilical Cord Mesenchymal Stem Cells to Treat Neuromyelitis Optica Spectrum Disorder (hUC-MSC-NMOSD): A Study Protocol for a Prospective, Multicenter, Randomized, Placebo-Controlled Clinical Trial. Front Neurol. 2022;13:860083. https:\/\/doi.org\/10.3389\/fneur.2022.860083.","journal-title":"Front Neurol"},{"issue":"21","key":"5058_CR70","doi-asserted-by":"publisher","first-page":"8341","DOI":"10.1073\/pnas.87.21.8341","volume":"87","author":"S Ikehara","year":"1990","unstructured":"Ikehara S, Kawamura M, Takao F, Inaba M, Yasumizu R, Than S, et al. Organ-specific and systemic autoimmune diseases originate from defects in hematopoietic stem cells. Proc Natl Acad Sci U S A. 1990;87(21):8341\u20134. https:\/\/doi.org\/10.1073\/pnas.87.21.8341.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"5058_CR71","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1073\/pnas.86.9.3306","volume":"86","author":"S Ikehara","year":"1989","unstructured":"Ikehara S, Yasumizu R, Inaba M, Izui S, Hayakawa K, Sekita K, et al. Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A. 1989;86(9):3306\u201310. https:\/\/doi.org\/10.1073\/pnas.86.9.3306.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"5058_CR72","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1002\/art.38879","volume":"66","author":"X Feng","year":"2014","unstructured":"Feng X, Che N, Liu Y, Chen H, Wang D, Li X, et al. Restored immunosuppressive effect of mesenchymal stem cells on B cells after olfactory 1\/early B cell factor-associated zinc-finger protein down-regulation in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2014;66(12):3413\u201323. https:\/\/doi.org\/10.1002\/art.38879.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"5058_CR73","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1002\/art.38674","volume":"66","author":"D Wang","year":"2014","unstructured":"Wang D, Feng X, Lu L, Konkel JE, Zhang H, Chen Z, et al. A CD8 T cell\/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus. Arthritis Rheumatol. 2014;66(8):2234\u201345. https:\/\/doi.org\/10.1002\/art.38674.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"5058_CR74","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0961203306075793","volume":"16","author":"LY Sun","year":"2007","unstructured":"Sun LY, Zhang HY, Feng XB, Hou YY, Lu LW, Fan LM. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus. 2007;16(2):121\u20138. https:\/\/doi.org\/10.1177\/0961203306075793.","journal-title":"Lupus"},{"key":"5058_CR75","doi-asserted-by":"publisher","first-page":"826182","DOI":"10.1155\/2012\/826182","volume":"2012","author":"Y Tang","year":"2012","unstructured":"Tang Y, Ma X, Zhang H, Gu Z, Hou Y, Gilkeson GS, et al. Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus. Clin Dev Immunol. 2012;2012:826182. https:\/\/doi.org\/10.1155\/2012\/826182.","journal-title":"Clin Dev Immunol"},{"issue":"2","key":"5058_CR76","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.clim.2012.08.012","volume":"145","author":"F Gu","year":"2012","unstructured":"Gu F, Molano I, Ruiz P, Sun L, Gilkeson GS. Differential effect of allogeneic versus syngeneic mesenchymal stem cell transplantation in MRL\/lpr and (NZB\/NZW)F1 mice. Clin Immunol. 2012;145(2):142\u201352. https:\/\/doi.org\/10.1016\/j.clim.2012.08.012.","journal-title":"Clin Immunol"},{"issue":"3","key":"5058_CR77","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1177\/0961203309348983","volume":"19","author":"F Carrion","year":"2010","unstructured":"Carrion F, Nova E, Ruiz C, Diaz F, Inostroza C, Rojo D, et al. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus. 2010;19(3):317\u201322. https:\/\/doi.org\/10.1177\/0961203309348983.","journal-title":"Lupus"},{"issue":"5","key":"5058_CR78","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/cmi.2015.89","volume":"14","author":"D Wang","year":"2017","unstructured":"Wang D, Huang S, Yuan X, Liang J, Xu R, Yao G, et al. The regulation of the Treg\/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol. 2017;14(5):423\u201331. https:\/\/doi.org\/10.1038\/cmi.2015.89.","journal-title":"Cell Mol Immunol"},{"key":"5058_CR79","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ebiom.2019.06.016","volume":"45","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Huang S, Wu S, Qi J, Li W, Liu S, et al. Clearance of apoptotic cells by mesenchymal stem cells contributes to immunosuppression via PGE2. EBioMedicine. 2019;45:341\u201350. https:\/\/doi.org\/10.1016\/j.ebiom.2019.06.016.","journal-title":"EBioMedicine"},{"issue":"1","key":"5058_CR80","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1038\/s41467-019-10491-8","volume":"10","author":"X Yuan","year":"2019","unstructured":"Yuan X, Qin X, Wang D, Zhang Z, Tang X, Gao X, et al. Mesenchymal stem cell therapy induces FLT3L and CD1c(+) dendritic cells in systemic lupus erythematosus patients. Nat Commun. 2019;10(1):2498. https:\/\/doi.org\/10.1038\/s41467-019-10491-8.","journal-title":"Nat Commun"},{"issue":"10","key":"5058_CR81","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.4049\/jimmunol.1400036","volume":"193","author":"N Che","year":"2014","unstructured":"Che N, Li X, Zhang L, Liu R, Chen H, Gao X, et al. Impaired B cell inhibition by lupus bone marrow mesenchymal stem cells is caused by reduced CCL2 expression. J Immunol. 2014;193(10):5306\u201314. https:\/\/doi.org\/10.4049\/jimmunol.1400036.","journal-title":"J Immunol"},{"issue":"2","key":"5058_CR82","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.clim.2015.07.011","volume":"161","author":"W Deng","year":"2015","unstructured":"Deng W, Chen W, Zhang Z, Huang S, Kong W, Sun Y, et al. Mesenchymal stem cells promote CD206 expression and phagocytic activity of macrophages through IL-6 in systemic lupus erythematosus. Clin Immunol. 2015;161(2):209\u201316. https:\/\/doi.org\/10.1016\/j.clim.2015.07.011.","journal-title":"Clin Immunol"},{"key":"5058_CR83","doi-asserted-by":"publisher","first-page":"530501","DOI":"10.1155\/2014\/530501","volume":"2014","author":"GP Ruan","year":"2014","unstructured":"Ruan GP, Yao X, Yang SJ, Wang JX, Shu F, Li ZA, et al. Transplanted human umbilical cord mesenchymal stem cells facilitate lesion repair in B6.Fas mice. J Immunol Res. 2014;2014:530501. https:\/\/doi.org\/10.1155\/2014\/530501.","journal-title":"J Immunol Res"},{"key":"5058_CR84","doi-asserted-by":"publisher","first-page":"728190","DOI":"10.3389\/fimmu.2021.728190","volume":"12","author":"A Li","year":"2021","unstructured":"Li A, Guo F, Pan Q, Chen S, Chen J, Liu HF, et al. Mesenchymal Stem Cell Therapy: Hope for Patients With Systemic Lupus Erythematosus. Front Immunol. 2021;12:728190. https:\/\/doi.org\/10.3389\/fimmu.2021.728190.","journal-title":"Front Immunol"},{"issue":"10","key":"5058_CR85","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.3889\/oamjms.2018.404","volume":"6","author":"A Putra","year":"2018","unstructured":"Putra A, Ridwan FB, Putridewi AI, Kustiyah AR, Wirastuti K, Sadyah NAC, et al. The Role of TNF-\u03b1 induced MSCs on Suppressive Inflammation by Increasing TGF-\u03b2 and IL-10. Open Access Maced J Med Sci. 2018;6(10):1779\u201383. https:\/\/doi.org\/10.3889\/oamjms.2018.404.","journal-title":"Open Access Maced J Med Sci"},{"issue":"6","key":"5058_CR86","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3727\/096368917x694660","volume":"26","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Feng R, Niu L, Huang S, Deng W, Shi B, et al. Human Umbilical Cord Mesenchymal Stem Cells Inhibit T Follicular Helper Cell Expansion Through the Activation of iNOS in Lupus-Prone B6.MRL-Fas(lpr) Mice. Cell Transpl. 2017;26(6):1031\u201342. https:\/\/doi.org\/10.3727\/096368917x694660.","journal-title":"Cell Transpl"},{"issue":"11","key":"5058_CR87","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.3727\/096368914x685645","volume":"24","author":"MJ Park","year":"2015","unstructured":"Park MJ, Kwok SK, Lee SH, Kim EK, Park SH, Cho ML. Adipose tissue-derived mesenchymal stem cells induce expansion of interleukin-10-producing regulatory B cells and ameliorate autoimmunity in a murine model of systemic lupus erythematosus. Cell Transpl. 2015;24(11):2367\u201377. https:\/\/doi.org\/10.3727\/096368914x685645.","journal-title":"Cell Transpl"},{"issue":"3","key":"5058_CR88","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/stem.2509","volume":"35","author":"LC Davies","year":"2017","unstructured":"Davies LC, Heldring N, Kadri N, Le Blanc K. Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression. Stem Cells. 2017;35(3):766\u201376. https:\/\/doi.org\/10.1002\/stem.2509.","journal-title":"Stem Cells"},{"issue":"4","key":"5058_CR89","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/art.40396","volume":"70","author":"S Karrar","year":"2018","unstructured":"Karrar S, Cunninghame Graham DS. Abnormal B Cell Development in Systemic Lupus Erythematosus: What the Genetics Tell Us. Arthritis Rheumatol. 2018;70(4):496\u2013507. https:\/\/doi.org\/10.1002\/art.40396.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"5058_CR90","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1182\/blood-2005-07-2657","volume":"107","author":"A Corcione","year":"2006","unstructured":"Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107(1):367\u201372. https:\/\/doi.org\/10.1182\/blood-2005-07-2657.","journal-title":"Blood"},{"issue":"9","key":"5058_CR91","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1002\/art.27560","volume":"62","author":"F Schena","year":"2010","unstructured":"Schena F, Gambini C, Gregorio A, Mosconi M, Reverberi D, Gattorno M, et al. Interferon-\u03b3-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum. 2010;62(9):2776\u201386. https:\/\/doi.org\/10.1002\/art.27560.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"5058_CR92","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12865-020-00388-3","volume":"21","author":"M Abbasifard","year":"2020","unstructured":"Abbasifard M, Kamiab Z, Hasani M, Rahnama A, Saeed-Askari P, Khorramdelazad H. Assessing the expression of immunosuppressive cytokines in the newly diagnosed systemic lupus Erythematosus patients: a focus on B cells. BMC Immunol. 2020;21(1):58. https:\/\/doi.org\/10.1186\/s12865-020-00388-3.","journal-title":"BMC Immunol"},{"key":"5058_CR93","doi-asserted-by":"publisher","first-page":"7948687","DOI":"10.1155\/2019\/7948687","volume":"2019","author":"T Wang","year":"2019","unstructured":"Wang T, Mei Y, Li Z. Research Progress on Regulatory B Cells in Systemic Lupus Erythematosus. Biomed Res Int. 2019;2019:7948687. https:\/\/doi.org\/10.1155\/2019\/7948687.","journal-title":"Biomed Res Int"},{"issue":"2","key":"5058_CR94","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/eji.201545760","volume":"46","author":"P Blanco","year":"2016","unstructured":"Blanco P, Ueno H, Schmitt N. T follicular helper (Tfh) cells in lupus: Activation and involvement in SLE pathogenesis. Eur J Immunol. 2016;46(2):281\u201390. https:\/\/doi.org\/10.1002\/eji.201545760.","journal-title":"Eur J Immunol"},{"issue":"1","key":"5058_CR95","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0961203317711013","volume":"27","author":"X Yang","year":"2018","unstructured":"Yang X, Yang J, Li X, Ma W, Zou H. Bone marrow-derived mesenchymal stem cells inhibit T follicular helper cell in lupus-prone mice. Lupus. 2018;27(1):49\u201359. https:\/\/doi.org\/10.1177\/0961203317711013.","journal-title":"Lupus"},{"issue":"2","key":"5058_CR96","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cyto.2014.12.027","volume":"72","author":"RM Talaat","year":"2015","unstructured":"Talaat RM, Mohamed SF, Bassyouni IH, Raouf AA. Th1\/Th2\/Th17\/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. Cytokine. 2015;72(2):146\u201353. https:\/\/doi.org\/10.1016\/j.cyto.2014.12.027.","journal-title":"Cytokine"},{"issue":"7","key":"5058_CR97","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1177\/0963689719837897","volume":"28","author":"A Musia\u0142-Wysocka","year":"2019","unstructured":"Musia\u0142-Wysocka A, Kot M, Majka M. The Pros and Cons of Mesenchymal Stem Cell-Based Therapies. Cell Transpl. 2019;28(7):801\u201312. https:\/\/doi.org\/10.1177\/0963689719837897.","journal-title":"Cell Transpl"},{"key":"5058_CR98","doi-asserted-by":"publisher","first-page":"9440377","DOI":"10.1155\/sci\/9440377","volume":"2025","author":"X Li","year":"2025","unstructured":"Li X, Li R, Huang J, Hu Y, Fan C, Wang X, et al. Unleashing the Potential: Exploring the Application and Mechanism of Mesenchymal Stem Cells in Autoimmune Diseases. Stem Cells Int. 2025;2025:9440377. https:\/\/doi.org\/10.1155\/sci\/9440377.","journal-title":"Stem Cells Int"},{"issue":"1","key":"5058_CR99","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12015-016-9703-3","volume":"13","author":"M Hajkova","year":"2017","unstructured":"Hajkova M, Hermankova B, Javorkova E, Bohacova P, Zajicova A, Holan V, et al. Mesenchymal Stem Cells Attenuate the Adverse Effects of Immunosuppressive Drugs on Distinct T Cell Subopulations. Stem Cell Rev Rep. 2017;13(1):104\u201315. https:\/\/doi.org\/10.1007\/s12015-016-9703-3.","journal-title":"Stem Cell Rev Rep"},{"key":"5058_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2019.06.009","volume":"207","author":"C Ma","year":"2019","unstructured":"Ma C, Xia Y, Yang Q, Zhao Y. The contribution of macrophages to systemic lupus erythematosus. Clin Immunol. 2019;207:1\u20139. https:\/\/doi.org\/10.1016\/j.clim.2019.06.009.","journal-title":"Clin Immunol"},{"issue":"4","key":"5058_CR101","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/ndt\/gfy195","volume":"34","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Niu L, Tang X, Feng R, Yao G, Chen W, et al. Mesenchymal stem cells prevent podocyte injury in lupus-prone B6.MRL-Faslpr mice via polarizing macrophage into an anti-inflammatory phenotype. Nephrol Dial Transpl. 2019;34(4):597\u2013605. https:\/\/doi.org\/10.1093\/ndt\/gfy195.","journal-title":"Nephrol Dial Transpl"},{"issue":"9","key":"5058_CR102","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1038\/s41375-020-0775-3","volume":"34","author":"C Xia","year":"2020","unstructured":"Xia C, Wang T, Cheng H, Dong Y, Weng Q, Sun G, et al. Mesenchymal stem cells suppress leukemia via macrophage-mediated functional restoration of bone marrow microenvironment. Leukemia. 2020;34(9):2375\u201383. https:\/\/doi.org\/10.1038\/s41375-020-0775-3.","journal-title":"Leukemia"},{"issue":"9","key":"5058_CR103","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.4049\/jimmunol.177.9.5878","volume":"177","author":"D Ding","year":"2006","unstructured":"Ding D, Mehta H, McCune WJ, Kaplan MJ. Aberrant phenotype and function of myeloid dendritic cells in systemic lupus erythematosus. J Immunol. 2006;177(9):5878\u201389. https:\/\/doi.org\/10.4049\/jimmunol.177.9.5878.","journal-title":"J Immunol"},{"issue":"1","key":"5058_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2567.2000.00044.x","volume":"100","author":"M Wykes","year":"2000","unstructured":"Wykes M, MacPherson G. Dendritic cell-B-cell interaction: dendritic cells provide B cells with CD40-independent proliferation signals and CD40-dependent survival signals. Immunology. 2000;100(1):1\u20133. https:\/\/doi.org\/10.1046\/j.1365-2567.2000.00044.x.","journal-title":"Immunology"},{"issue":"3","key":"5058_CR105","doi-asserted-by":"publisher","first-page":"808","DOI":"10.2741\/3279","volume":"14","author":"N Kadowaki","year":"2009","unstructured":"Kadowaki N. The divergence and interplay between pDC and mDC in humans. Front Biosci (Landmark Ed). 2009;14(3):808\u201317. https:\/\/doi.org\/10.2741\/3279.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"5","key":"5058_CR106","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/BOR.0b013e3283562c3e","volume":"24","author":"KB Elkon","year":"2012","unstructured":"Elkon KB, Wiedeman A. Type I IFN system in the development and manifestations of SLE. Curr Opin Rheumatol. 2012;24(5):499\u2013505. https:\/\/doi.org\/10.1097\/BOR.0b013e3283562c3e.","journal-title":"Curr Opin Rheumatol"},{"issue":"10","key":"5058_CR107","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1182\/blood-2004-02-0586","volume":"105","author":"XX Jiang","year":"2005","unstructured":"Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 2005;105(10):4120\u20136. https:\/\/doi.org\/10.1182\/blood-2004-02-0586.","journal-title":"Blood"},{"issue":"1","key":"5058_CR108","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1182\/blood-2008-04-154138","volume":"113","author":"B Zhang","year":"2009","unstructured":"Zhang B, Liu R, Shi D, Liu X, Chen Y, Dou X, et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood. 2009;113(1):46\u201357. https:\/\/doi.org\/10.1182\/blood-2008-04-154138.","journal-title":"Blood"},{"issue":"1","key":"5058_CR109","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s13287-019-1488-2","volume":"10","author":"Z Lu","year":"2019","unstructured":"Lu Z, Chang W, Meng S, Xu X, Xie J, Guo F, et al. Mesenchymal stem cells induce dendritic cell immune tolerance via paracrine hepatocyte growth factor to alleviate acute lung injury. Stem Cell Res Ther. 2019;10(1):372. https:\/\/doi.org\/10.1186\/s13287-019-1488-2.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"5058_CR110","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1182\/blood-2004-04-1559","volume":"105","author":"S Aggarwal","year":"2005","unstructured":"Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815\u201322. https:\/\/doi.org\/10.1182\/blood-2004-04-1559.","journal-title":"Blood"},{"key":"5058_CR111","doi-asserted-by":"publisher","first-page":"604607","DOI":"10.3389\/fimmu.2020.604607","volume":"11","author":"J Tian","year":"2020","unstructured":"Tian J, Hong Y, Zhu Q, Zhou H, Zhang Y, Shen Z, et al. Mesenchymal Stem Cell Enhances the Function of MDSCs in Experimental Sj\u00f6gren Syndrome. Front Immunol. 2020;11:604607. https:\/\/doi.org\/10.3389\/fimmu.2020.604607.","journal-title":"Front Immunol"},{"issue":"2","key":"5058_CR112","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/ar4520","volume":"16","author":"D Wang","year":"2014","unstructured":"Wang D, Li J, Zhang Y, Zhang M, Chen J, Li X, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther. 2014;16(2):R79. https:\/\/doi.org\/10.1186\/ar4520.","journal-title":"Arthritis Res Ther"},{"key":"5058_CR113","doi-asserted-by":"publisher","unstructured":"Bonig H, Ku\u00e7i Z, Ku\u00e7i S, Bakhtiar S, Basu O, Bug G, et al. Children and adults with refractory acute graft-versus-host disease respond to treatment with the mesenchymal stromal cell preparation MSC-FFM-outcome report of 92 patients. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8121577.","DOI":"10.3390\/cells8121577"},{"issue":"2","key":"5058_CR114","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3390\/ph8020196","volume":"8","author":"JP McGuirk","year":"2015","unstructured":"McGuirk JP, Smith JR, Divine CL, Zuniga M, Weiss ML. Wharton\u2019s Jelly-Derived Mesenchymal Stromal Cells as a Promising Cellular Therapeutic Strategy for the Management of Graft-versus-Host Disease. Pharmaceuticals (Basel). 2015;8(2):196\u2013220. https:\/\/doi.org\/10.3390\/ph8020196.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"5058_CR115","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/s2352-3026(15)00224-0","volume":"3","author":"S Hashmi","year":"2016","unstructured":"Hashmi S, Ahmed M, Murad MH, Litzow MR, Adams RH, Ball LM, et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol. 2016;3(1):e45\u201352. https:\/\/doi.org\/10.1016\/s2352-3026(15)00224-0.","journal-title":"Lancet Haematol"},{"issue":"1","key":"5058_CR116","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13287-020-01592-z","volume":"11","author":"C Morata-Tarifa","year":"2020","unstructured":"Morata-Tarifa C, Mac\u00edas-S\u00e1nchez MDM, Guti\u00e9rrez-Pizarraya A, Sanchez-Pernaute R. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis. Stem Cell Res Ther. 2020;11(1):64. https:\/\/doi.org\/10.1186\/s13287-020-01592-z.","journal-title":"Stem Cell Res Ther"},{"issue":"13","key":"5058_CR117","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1177\/0961203310373782","volume":"19","author":"Z Gu","year":"2010","unstructured":"Gu Z, Akiyama K, Ma X, Zhang H, Feng X, Yao G, et al. Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL\/lpr mice. Lupus. 2010;19(13):1502\u201314. https:\/\/doi.org\/10.1177\/0961203310373782.","journal-title":"Lupus"},{"key":"5058_CR118","doi-asserted-by":"publisher","first-page":"273291","DOI":"10.1155\/2012\/273291","volume":"2012","author":"D Wang","year":"2012","unstructured":"Wang D, Akiyama K, Zhang H, Yamaza T, Li X, Feng X, et al. Double allogenic mesenchymal stem cells transplantations could not enhance therapeutic effect compared with single transplantation in systemic lupus erythematosus. Clin Dev Immunol. 2012;2012:273291. https:\/\/doi.org\/10.1155\/2012\/273291.","journal-title":"Clin Dev Immunol"},{"issue":"10","key":"5058_CR119","doi-asserted-by":"publisher","first-page":"e1181","DOI":"10.1002\/cti2.1181","volume":"9","author":"W Li","year":"2020","unstructured":"Li W, Chen W, Huang S, Yao G, Tang X, Sun L. Mesenchymal stem cells prevent overwhelming inflammation and reduce infection severity via recruiting CXCR3(+) regulatory T cells. Clin Transl Immunol. 2020;9(10):e1181. https:\/\/doi.org\/10.1002\/cti2.1181.","journal-title":"Clin Transl Immunol"},{"issue":"1","key":"5058_CR120","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s13287-020-01807-3","volume":"11","author":"H Yagi","year":"2020","unstructured":"Yagi H, Chen AF, Hirsch D, Rothenberg AC, Tan J, Alexander PG, et al. Antimicrobial activity of mesenchymal stem cells against Staphylococcus aureus. Stem Cell Res Ther. 2020;11(1):293. https:\/\/doi.org\/10.1186\/s13287-020-01807-3.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"5058_CR121","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/mmy\/myv110","volume":"54","author":"SY Cho","year":"2016","unstructured":"Cho SY, Kwon EY, Choi SM, Lee DG, Park C, Park SH, et al. Immunomodulatory effect of mesenchymal stem cells on the immune response of macrophages stimulated by Aspergillus fumigatus conidia. Med Mycol. 2016;54(4):377\u201383. https:\/\/doi.org\/10.1093\/mmy\/myv110.","journal-title":"Med Mycol"},{"issue":"6","key":"5058_CR122","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1097\/aln.0000000000001882","volume":"127","author":"C Keane","year":"2017","unstructured":"Keane C, Jerkic M, Laffey JG. Stem Cell-based Therapies for Sepsis. Anesthesiology. 2017;127(6):1017\u201334. https:\/\/doi.org\/10.1097\/aln.0000000000001882.","journal-title":"Anesthesiology"},{"issue":"3","key":"5058_CR123","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s12015-020-09973-w","volume":"16","author":"A Golchin","year":"2020","unstructured":"Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future. Stem Cell Rev Rep. 2020;16(3):427\u201333. https:\/\/doi.org\/10.1007\/s12015-020-09973-w.","journal-title":"Stem Cell Rev Rep"},{"issue":"1","key":"5058_CR124","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s13287-020-01875-5","volume":"11","author":"L Shu","year":"2020","unstructured":"Shu L, Niu C, Li R, Huang T, Wang Y, Huang M, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11(1):361. https:\/\/doi.org\/10.1186\/s13287-020-01875-5.","journal-title":"Stem Cell Res Ther"},{"key":"5058_CR125","doi-asserted-by":"publisher","first-page":"9370919","DOI":"10.1155\/2019\/9370919","volume":"2019","author":"J Liu","year":"2019","unstructured":"Liu J, Lu X, Lou Y, Cai Y, Cui W, Wang J, et al. Xenogeneic Transplantation of Human Placenta-Derived Mesenchymal Stem Cells Alleviates Renal Injury and Reduces Inflammation in a Mouse Model of Lupus Nephritis. Biomed Res Int. 2019;2019:9370919. https:\/\/doi.org\/10.1155\/2019\/9370919.","journal-title":"Biomed Res Int"},{"key":"5058_CR126","doi-asserted-by":"publisher","first-page":"17685","DOI":"10.1038\/srep17685","volume":"5","author":"A Thiel","year":"2015","unstructured":"Thiel A, Yavanian G, Nastke MD, Morales P, Kouris NA, Kimbrel EA, et al. Human embryonic stem cell-derived mesenchymal cells preserve kidney function and extend lifespan in NZB\/W F1 mouse model of lupus nephritis. Sci Rep. 2015;5:17685. https:\/\/doi.org\/10.1038\/srep17685.","journal-title":"Sci Rep"},{"issue":"7","key":"5058_CR127","doi-asserted-by":"publisher","first-page":"132","DOI":"10.21037\/atm.2019.02.41","volume":"7","author":"X Tang","year":"2019","unstructured":"Tang X, Li W, Wen X, Zhang Z, Chen W, Yao G, et al. Transplantation of dental tissue-derived mesenchymal stem cells ameliorates nephritis in lupus mice. Ann Transl Med. 2019;7(7):132. https:\/\/doi.org\/10.21037\/atm.2019.02.41.","journal-title":"Ann Transl Med"},{"issue":"1","key":"5058_CR128","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1681\/asn.2019050545","volume":"31","author":"J Xu","year":"2020","unstructured":"Xu J, Chen J, Li W, Lian W, Huang J, Lai B, et al. Additive Therapeutic Effects of Mesenchymal Stem Cells and IL-37 for Systemic Lupus Erythematosus. J Am Soc Nephrol. 2020;31(1):54\u201365. https:\/\/doi.org\/10.1681\/asn.2019050545.","journal-title":"J Am Soc Nephrol"},{"issue":"1\u20134","key":"5058_CR129","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.bbrc.2018.10.133","volume":"507","author":"S Huang","year":"2018","unstructured":"Huang S, Wu S, Zhang Z, Deng W, Fan J, Feng R, et al. Mesenchymal stem cells induced CD4\u2009+\u2009T cell apoptosis in treatment of lupus mice. Biochem Biophys Res Commun. 2018;507(1\u20134):30\u20135. https:\/\/doi.org\/10.1016\/j.bbrc.2018.10.133.","journal-title":"Biochem Biophys Res Commun"},{"key":"5058_CR130","doi-asserted-by":"publisher","unstructured":"Han X, Wang D, Chen L, Song H, Zheng X, Zhang X, et al. MSC transplantation ameliorates depression in lupus by suppressing Th1 cell-shaped synaptic stripping. JCI Insight. 2025. https:\/\/doi.org\/10.1172\/jci.insight.181885.","DOI":"10.1172\/jci.insight.181885"},{"key":"5058_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.01.044","author":"S Liao","year":"2025","unstructured":"Liao S, Guo F, Xiao Z, Xiao H, Pan QR, Guo Y, et al. Autophagy activation within inflammatory microenvironment improved the therapeutic effect of MSC-Derived extracellular Vesicle in SLE. J Adv Res. 2025. https:\/\/doi.org\/10.1016\/j.jare.2025.01.044.","journal-title":"J Adv Res"},{"issue":"1","key":"5058_CR132","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13287-023-03432-2","volume":"14","author":"F Guo","year":"2023","unstructured":"Guo F, Pan Q, Chen T, Liao S, Li S, Li A, et al. hUC-MSC transplantation therapy effects on lupus-prone MRL\/lpr mice at early disease stages. Stem Cell Res Ther. 2023;14(1):211. https:\/\/doi.org\/10.1186\/s13287-023-03432-2.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"5058_CR133","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.stemcr.2018.01.029","volume":"10","author":"D Wang","year":"2018","unstructured":"Wang D, Zhang H, Liang J, Wang H, Hua B, Feng X, et al. A Long-Term Follow-Up Study of Allogeneic Mesenchymal Stem\/Stromal Cell Transplantation in Patients with Drug-Resistant Systemic Lupus Erythematosus. Stem Cell Rep. 2018;10(3):933\u201341. https:\/\/doi.org\/10.1016\/j.stemcr.2018.01.029.","journal-title":"Stem Cell Rep"},{"issue":"5","key":"5058_CR134","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00296-010-1588-x","volume":"31","author":"J Meng","year":"2011","unstructured":"Meng J, Wang J, Liang W, Qin S, Wu C. Long-term remission after successful pregnancy in autologous peripheral blood stem cell transplanted system lupus erythematosus patients. Rheumatol Int. 2011;31(5):691\u20134. https:\/\/doi.org\/10.1007\/s00296-010-1588-x.","journal-title":"Rheumatol Int"},{"issue":"1","key":"5058_CR135","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5455\/aim.2023.31.20-25","volume":"31","author":"DM Darlan","year":"2023","unstructured":"Darlan DM, Raga A, Muhar AM, Putra A, Alif I. Mesenchymal Stem Cells Suppress Dendritic Cells and Modulate Proinflammatory Milieu Through Interleukin-10 Expression in Peripheral Blood Mononuclear Cells of Human Systemic Lupus Erythematosus. Acta Inf Med. 2023;31(1):20\u20135. https:\/\/doi.org\/10.5455\/aim.2023.31.20-25.","journal-title":"Acta Inf Med"},{"issue":"8","key":"5058_CR136","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1136\/annrheumdis-2017-211073","volume":"76","author":"D Deng","year":"2017","unstructured":"Deng D, Zhang P, Guo Y, Lim TO. A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis. Ann Rheum Dis. 2017;76(8):1436\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211073.","journal-title":"Ann Rheum Dis"},{"key":"5058_CR137","doi-asserted-by":"publisher","unstructured":"Kamen DL, Wallace C, Li Z, Wyatt M, Paulos C, Wei C, et al. Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE. Lupus Sci Med. 2022. https:\/\/doi.org\/10.1136\/lupus-2022-000704.","DOI":"10.1136\/lupus-2022-000704"},{"issue":"10","key":"5058_CR138","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1177\/09612033221111957","volume":"31","author":"S Chun","year":"2022","unstructured":"Chun S, Choi CB, Kim MS, Nam JY, Lee TY, Lee YT, et al. Safety and tolerability of bone marrow-derived mesenchymal stem cells in lupus animal models and a phase I clinical trial in humans. Lupus. 2022;31(10):1245\u201353. https:\/\/doi.org\/10.1177\/09612033221111957.","journal-title":"Lupus"},{"issue":"2","key":"5058_CR139","doi-asserted-by":"publisher","first-page":"103324","DOI":"10.1016\/j.retram.2021.103324","volume":"70","author":"A Ranjbar","year":"2022","unstructured":"Ranjbar A, Hassanzadeh H, Jahandoust F, Miri R, Bidkhori HR, Monzavi SM, et al. Allogeneic adipose-derived mesenchymal stromal cell transplantation for refractory lupus nephritis: Results of a phase I clinical trial. Curr Res Transl Med. 2022;70(2):103324. https:\/\/doi.org\/10.1016\/j.retram.2021.103324.","journal-title":"Curr Res Transl Med"},{"issue":"9","key":"5058_CR140","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1517\/14712598.2015.1051528","volume":"15","author":"T Li","year":"2015","unstructured":"Li T, Xia M, Gao Y, Chen Y, Xu Y. Human umbilical cord mesenchymal stem cells: an overview of their potential in cell-based therapy. Expert Opin Biol Ther. 2015;15(9):1293\u2013306. https:\/\/doi.org\/10.1517\/14712598.2015.1051528.","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"5058_CR141","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.3727\/096368911X582769c","volume":"22","author":"D Wang","year":"2013","unstructured":"Wang D, Zhang H, Liang J, Li X, Feng X, Wang H, et al. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transpl. 2013;22(12):2267\u201377. https:\/\/doi.org\/10.3727\/096368911X582769c.","journal-title":"Cell Transpl"},{"issue":"1","key":"5058_CR142","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s13287-018-1053-4","volume":"9","author":"J Liang","year":"2018","unstructured":"Liang J, Zhang H, Kong W, Deng W, Wang D, Feng X, et al. Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study. Stem Cell Res Ther. 2018;9(1):312. https:\/\/doi.org\/10.1186\/s13287-018-1053-4.","journal-title":"Stem Cell Res Ther"},{"issue":"11","key":"5058_CR143","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s10067-014-2754-4","volume":"33","author":"F Gu","year":"2014","unstructured":"Gu F, Wang D, Zhang H, Feng X, Gilkeson GS, Shi S, et al. Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. Clin Rheumatol. 2014;33(11):1611\u20139. https:\/\/doi.org\/10.1007\/s10067-014-2754-4.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"5058_CR144","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1002\/art.27548","volume":"62","author":"L Sun","year":"2010","unstructured":"Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010;62(8):2467\u201375. https:\/\/doi.org\/10.1002\/art.27548.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"5058_CR145","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/ard.2009.123463","volume":"69","author":"J Liang","year":"2010","unstructured":"Liang J, Zhang H, Hua B, Wang H, Lu L, Shi S, et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis. 2010;69(8):1423\u20139. https:\/\/doi.org\/10.1136\/ard.2009.123463.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5058_CR146","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/bmt.2012.184","volume":"48","author":"X Li","year":"2013","unstructured":"Li X, Wang D, Liang J, Zhang H, Sun L. Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus. Bone Marrow Transpl. 2013;48(4):544\u201350. https:\/\/doi.org\/10.1038\/bmt.2012.184.","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"5058_CR147","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nrrheum.2010.80","volume":"6","author":"J Liang","year":"2010","unstructured":"Liang J, Gu F, Wang H, Hua B, Hou Y, Shi S, et al. Mesenchymal stem cell transplantation for diffuse alveolar hemorrhage in SLE. Nat Rev Rheumatol. 2010;6(8):486\u20139. https:\/\/doi.org\/10.1038\/nrrheum.2010.80.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"5058_CR148","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1186\/s13287-025-04515-y","volume":"16","author":"S Wu","year":"2025","unstructured":"Wu S, Ding S, Wang Y, Li S, Ying Z. Review: progression and heterogeneity of multiple sources of mesenchymal stromal cells for the treatment of rheumatoid arthritis. Stem Cell Res Ther. 2025;16(1):358. https:\/\/doi.org\/10.1186\/s13287-025-04515-y.","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"5058_CR149","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1002\/art.27371","volume":"62","author":"M Petri","year":"2010","unstructured":"Petri M, Brodsky RA, Jones RJ, Gladstone D, Fillius M, Magder LS. High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. Arthritis Rheum. 2010;62(5):1487\u201393. https:\/\/doi.org\/10.1002\/art.27371.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"5058_CR150","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1001\/jama.295.5.559","volume":"295","author":"M Petri","year":"2006","unstructured":"Petri M, Brodsky R. High-dose cyclophosphamide and stem cell transplantation for refractory systemic lupus erythematosus. JAMA. 2006;295(5):559\u201360. https:\/\/doi.org\/10.1001\/jama.295.5.559.","journal-title":"JAMA"},{"issue":"1","key":"5058_CR151","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/art.10752","volume":"48","author":"M Petri","year":"2003","unstructured":"Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum. 2003;48(1):166\u201373. https:\/\/doi.org\/10.1002\/art.10752.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"5058_CR152","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1191\/0961203304lu1027oa","volume":"13","author":"D Jayne","year":"2004","unstructured":"Jayne D, Tyndall A. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus. 2004;13(5):359\u201365. https:\/\/doi.org\/10.1191\/0961203304lu1027oa.","journal-title":"Lupus"},{"issue":"6","key":"5058_CR153","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/stem.68","volume":"27","author":"L Sun","year":"2009","unstructured":"Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S, et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells. 2009;27(6):1421\u201332. https:\/\/doi.org\/10.1002\/stem.68.","journal-title":"Stem Cells"},{"key":"5058_CR154","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.biopha.2017.10.114","volume":"97","author":"E Javorkova","year":"2018","unstructured":"Javorkova E, Vackova J, Hajkova M, Hermankova B, Zajicova A, Holan V, et al. The effect of clinically relevant doses of immunosuppressive drugs on human mesenchymal stem cells. Biomed Pharmacother. 2018;97:402\u201311. https:\/\/doi.org\/10.1016\/j.biopha.2017.10.114.","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"5058_CR155","doi-asserted-by":"publisher","first-page":"879","DOI":"10.4252\/wjsc.v12.i8.879","volume":"12","author":"JH Wang","year":"2020","unstructured":"Wang JH, Liu XL, Sun JM, Yang JH, Xu DH, Yan SS. Role of mesenchymal stem cell derived extracellular vesicles in autoimmunity: A systematic review. World J Stem Cells. 2020;12(8):879\u201396. https:\/\/doi.org\/10.4252\/wjsc.v12.i8.879.","journal-title":"World J Stem Cells"},{"key":"5058_CR156","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40364-019-0156-0","volume":"7","author":"P Lai","year":"2019","unstructured":"Lai P, Weng J, Guo L, Chen X, Du X. Novel insights into MSC-EVs therapy for immune diseases. Biomark Res. 2019;7:6. https:\/\/doi.org\/10.1186\/s40364-019-0156-0.","journal-title":"Biomark Res"},{"issue":"10","key":"5058_CR157","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.4155\/fmc-2018-0417","volume":"11","author":"W Whitford","year":"2019","unstructured":"Whitford W, Guterstam P. Exosome manufacturing status. Future Med Chem. 2019;11(10):1225\u201336. https:\/\/doi.org\/10.4155\/fmc-2018-0417.","journal-title":"Future Med Chem"},{"key":"5058_CR158","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13045-015-0220-7","volume":"8","author":"G Lou","year":"2015","unstructured":"Lou G, Song X, Yang F, Wu S, Wang J, Chen Z, et al. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. J Hematol Oncol. 2015;8:122. https:\/\/doi.org\/10.1186\/s13045-015-0220-7.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"5058_CR159","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.26355\/eurrev_202004_20975","volume":"24","author":"B Yuan","year":"2020","unstructured":"Yuan B, Pan S, Dong YQ, Zhang WW, He XD. Effect of exosomes derived from mir-126-modified mesenchymal stem cells on the repair process of spinal cord injury in rats. Eur Rev Med Pharmacol Sci. 2020;24(8):4058. https:\/\/doi.org\/10.26355\/eurrev_202004_20975.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"5058_CR160","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5966\/sctm.2016-0038","volume":"6","author":"J Ma","year":"2017","unstructured":"Ma J, Zhao Y, Sun L, Sun X, Zhao X, Sun X, et al. Exosomes Derived from Akt-Modified Human Umbilical Cord Mesenchymal Stem Cells Improve Cardiac Regeneration and Promote Angiogenesis via Activating Platelet-Derived Growth Factor D. Stem Cells Transl Med. 2017;6(1):51\u20139. https:\/\/doi.org\/10.5966\/sctm.2016-0038.","journal-title":"Stem Cells Transl Med"},{"issue":"8","key":"5058_CR161","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.4049\/jimmunol.1800304","volume":"201","author":"Z Chen","year":"2018","unstructured":"Chen Z, Wang H, Xia Y, Yan F, Lu Y. Therapeutic Potential of Mesenchymal Cell-Derived miRNA-150-5p-Expressing Exosomes in Rheumatoid Arthritis Mediated by the Modulation of MMP14 and VEGF. J Immunol. 2018;201(8):2472\u201382. https:\/\/doi.org\/10.4049\/jimmunol.1800304.","journal-title":"J Immunol"},{"key":"5058_CR162","doi-asserted-by":"publisher","unstructured":"Niu L, Ou Q, Ren Q, Li Z, Chen H, Lei F, et al. Engineered Foxp1(high) exosomes ameliorates systemic lupus erythematosus. Adv Sci (Weinh). 2025. https:\/\/doi.org\/10.1002\/advs.202415712.","DOI":"10.1002\/advs.202415712"},{"issue":"1","key":"5058_CR163","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4049\/jimmunol.178.1.280","volume":"178","author":"MA Burchill","year":"2007","unstructured":"Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3\u2009+\u2009regulatory T cells. J Immunol. 2007;178(1):280\u201390. https:\/\/doi.org\/10.4049\/jimmunol.178.1.280.","journal-title":"J Immunol"},{"issue":"5","key":"5058_CR164","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.immuni.2021.03.020","volume":"54","author":"S Dikiy","year":"2021","unstructured":"Dikiy S, Li J, Bai L, Jiang M, Janke L, Zong X, et al. A distal Foxp3 enhancer enables interleukin-2 dependent thymic Treg cell lineage commitment for robust immune tolerance. Immunity. 2021;54(5):931\u2013e4611. https:\/\/doi.org\/10.1016\/j.immuni.2021.03.020.","journal-title":"Immunity"},{"issue":"1","key":"5058_CR165","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nyas.13011","volume":"1417","author":"R Bacchetta","year":"2018","unstructured":"Bacchetta R, Barzaghi F, Roncarolo MG. From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation. Ann N Y Acad Sci. 2018;1417(1):5\u201322. https:\/\/doi.org\/10.1111\/nyas.13011.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"5058_CR166","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1038\/s41467-018-07018-y","volume":"9","author":"S Ghosh","year":"2018","unstructured":"Ghosh S, Roy-Chowdhuri S, Kang K, Im SH, Rudra D. The transcription factor Foxp1 preserves integrity of an active Foxp3 locus in extrathymic Treg cells. Nat Commun. 2018;9(1):4473. https:\/\/doi.org\/10.1038\/s41467-018-07018-y.","journal-title":"Nat Commun"},{"issue":"12","key":"5058_CR167","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","volume":"12","author":"GC Tsokos","year":"2016","unstructured":"Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716\u201330. https:\/\/doi.org\/10.1038\/nrrheum.2016.186.","journal-title":"Nat Rev Rheumatol"},{"issue":"20","key":"5058_CR168","doi-asserted-by":"publisher","first-page":"13249","DOI":"10.1021\/acsnano.4c02420","volume":"18","author":"W Ma","year":"2024","unstructured":"Ma W, Che J, Chen W, Wang D, Zhang H, Zhao Y. Dexamethasone-Integrated Mesenchymal Stem Cells for Systemic Lupus Erythematosus Treatment via Multiple Immunomodulatory Mechanisms. ACS Nano. 2024;18(20):13249\u201365. https:\/\/doi.org\/10.1021\/acsnano.4c02420.","journal-title":"ACS Nano"},{"key":"5058_CR169","doi-asserted-by":"publisher","first-page":"1476859","DOI":"10.3389\/fimmu.2024.1476859","volume":"15","author":"J Zhou","year":"2024","unstructured":"Zhou J, Lei B, Shi F, Luo X, Wu K, Xu Y, et al. CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives. Front Immunol. 2024;15:1476859. https:\/\/doi.org\/10.3389\/fimmu.2024.1476859.","journal-title":"Front Immunol"},{"key":"5058_CR170","doi-asserted-by":"publisher","first-page":"1625166","DOI":"10.3389\/fimmu.2025.1625166","volume":"16","author":"Y Wu","year":"2025","unstructured":"Wu Y, Han L, Wang Y, Gu M, Wang Y, Gao J, et al. CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases. Front Immunol. 2025;16:1625166. https:\/\/doi.org\/10.3389\/fimmu.2025.1625166.","journal-title":"Front Immunol"},{"issue":"10","key":"5058_CR171","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.4049\/jimmunol.165.10.5970","volume":"165","author":"M Odendahl","year":"2000","unstructured":"Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol. 2000;165(10):5970\u20139. https:\/\/doi.org\/10.4049\/jimmunol.165.10.5970.","journal-title":"J Immunol"},{"issue":"Suppl 5","key":"5058_CR172","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar3909","volume":"14","author":"HE Mei","year":"2012","unstructured":"Mei HE, Schmidt S, D\u00f6rner T. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther. 2012;14(Suppl 5):S1. https:\/\/doi.org\/10.1186\/ar3909.","journal-title":"Arthritis Res Ther"},{"key":"5058_CR173","doi-asserted-by":"publisher","unstructured":"Kansal R, Richardson N, Neeli I, Khawaja S, Chamberlain D, Ghani M, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aav1648.","DOI":"10.1126\/scitranslmed.aav1648"},{"issue":"8","key":"5058_CR174","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","volume":"18","author":"X Jin","year":"2021","unstructured":"Jin X, Xu Q, Pu C, Zhu K, Lu C, Jiang Y, et al. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol. 2021;18(8):1896\u2013903. https:\/\/doi.org\/10.1038\/s41423-020-0472-1.","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"5058_CR175","doi-asserted-by":"publisher","first-page":"100080","DOI":"10.1016\/j.xcrm.2020.100080","volume":"1","author":"SD Reighard","year":"2020","unstructured":"Reighard SD, Cranert SA, Rangel KM, Ali A, Gyurova IE, de la Cruz-Lynch AT, et al. Erratum: Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells. Cell Rep Med. 2020;1(5):100080. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100080.","journal-title":"Cell Rep Med"},{"issue":"6","key":"5058_CR176","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N Engl J Med. 2021;385(6):567\u20139. https:\/\/doi.org\/10.1056\/NEJMc2107725.","journal-title":"N Engl J Med"},{"issue":"10","key":"5058_CR177","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, B\u00f6ltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124\u201332. https:\/\/doi.org\/10.1038\/s41591-022-02017-5.","journal-title":"Nat Med"},{"issue":"6","key":"5058_CR178","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","volume":"17","author":"W Zhang","year":"2021","unstructured":"Zhang W, Feng J, Cinquina A, Wang Q, Xu H, Zhang Q, et al. Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR. Stem Cell Rev Rep. 2021;17(6):2120\u20133. https:\/\/doi.org\/10.1007\/s12015-021-10251-6.","journal-title":"Stem Cell Rev Rep"},{"key":"5058_CR179","doi-asserted-by":"publisher","first-page":"101104","DOI":"10.1016\/j.omtm.2023.08.023","volume":"31","author":"D Nunez","year":"2023","unstructured":"Nunez D, Patel D, Volkov J, Wong S, Vorndran Z, M\u00fcller F, et al. Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy. Mol Ther Methods Clin Dev. 2023;31:101104. https:\/\/doi.org\/10.1016\/j.omtm.2023.08.023.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"5058_CR180","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.stem.2022.01.007","volume":"29","author":"H Okano","year":"2022","unstructured":"Okano H, Morimoto S. iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders. Cell Stem Cell. 2022;29(2):189\u2013208. https:\/\/doi.org\/10.1016\/j.stem.2022.01.007.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"5058_CR181","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s41232-023-00303-4","volume":"43","author":"H Shoda","year":"2023","unstructured":"Shoda H, Natsumoto B, Fujio K. Investigation of immune-related diseases using patient-derived induced pluripotent stem cells. Inflamm Regen. 2023;43(1):51. https:\/\/doi.org\/10.1186\/s41232-023-00303-4.","journal-title":"Inflamm Regen"},{"key":"5058_CR182","doi-asserted-by":"publisher","first-page":"103085","DOI":"10.1016\/j.jaut.2023.103085","volume":"139","author":"B Natsumoto","year":"2023","unstructured":"Natsumoto B, Shoda H, Nagafuchi Y, Ota M, Okumura T, Horie Y, et al. Functional evaluation of rare OASL variants by analysis of SLE patient-derived iPSCs. J Autoimmun. 2023;139:103085. https:\/\/doi.org\/10.1016\/j.jaut.2023.103085.","journal-title":"J Autoimmun"},{"issue":"5","key":"5058_CR183","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1038\/emm.2016.27","volume":"48","author":"MY Son","year":"2016","unstructured":"Son MY, Lee MO, Jeon H, Seol B, Kim JH, Chang JS, et al. Generation and characterization of integration-free induced pluripotent stem cells from patients with autoimmune disease. Exp Mol Med. 2016;48(5):e232. https:\/\/doi.org\/10.1038\/emm.2016.27.","journal-title":"Exp Mol Med"},{"issue":"3","key":"5058_CR184","doi-asserted-by":"publisher","first-page":"273","DOI":"10.22074\/cellj.2021.7244","volume":"23","author":"S Gholami","year":"2021","unstructured":"Gholami S, Mazidi Z, Pahlavan S, Moslem F, Hosseini M, Taei A, et al. A Novel Insight into Endothelial and Cardiac Cells Phenotype in Systemic Sclerosis Using Patient-Derived Induced Pluripotent Stem Cell. Cell J. 2021;23(3):273\u201387. https:\/\/doi.org\/10.22074\/cellj.2021.7244.","journal-title":"Cell J"},{"issue":"8","key":"5058_CR185","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s00296-013-2704-5","volume":"33","author":"Y Chen","year":"2013","unstructured":"Chen Y, Luo R, Xu Y, Cai X, Li W, Tan K, et al. Generation of systemic lupus erythematosus-specific induced pluripotent stem cells from urine. Rheumatol Int. 2013;33(8):2127\u201334. https:\/\/doi.org\/10.1007\/s00296-013-2704-5.","journal-title":"Rheumatol Int"},{"key":"5058_CR186","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1186\/s12864-016-2809-9","volume":"17","author":"D Tang","year":"2016","unstructured":"Tang D, Chen Y, He H, Huang J, Chen W, Peng W, et al. Integrated analysis of mRNA, microRNA and protein in systemic lupus erythematosus-specific induced pluripotent stem cells from urine. BMC Genomics. 2016;17:488. https:\/\/doi.org\/10.1186\/s12864-016-2809-9.","journal-title":"BMC Genomics"},{"issue":"11","key":"5058_CR187","doi-asserted-by":"publisher","first-page":"7382","DOI":"10.1111\/jcmm.14598","volume":"23","author":"MT De Angelis","year":"2019","unstructured":"De Angelis MT, Santamaria G, Parrotta EI, Scalise S, Lo Conte M, Gasparini S, et al. Establishment and characterization of induced pluripotent stem cells (iPSCs) from central nervous system lupus erythematosus. J Cell Mol Med. 2019;23(11):7382\u201394. https:\/\/doi.org\/10.1111\/jcmm.14598.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"5058_CR188","doi-asserted-by":"publisher","first-page":"233","DOI":"10.15283\/ijsc21158","volume":"15","author":"N Park","year":"2022","unstructured":"Park N, Rim YA, Jung H, Nam Y, Ju JH. Lupus Heart Disease Modeling with Combination of Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Lupus Patient Serum. Int J Stem Cells. 2022;15(3):233\u201346. https:\/\/doi.org\/10.15283\/ijsc21158.","journal-title":"Int J Stem Cells"},{"key":"5058_CR189","doi-asserted-by":"publisher","first-page":"102192","DOI":"10.1016\/j.scr.2021.102192","volume":"51","author":"D Li","year":"2021","unstructured":"Li D, Hong X, Li W, Meng S, Yu H, Zhang X, et al. Establishment of an induced pluripotent stem cell line SPHi001-A from a systemic lupus erythematosus patient combined with preeclampsia and psoriasis. Stem Cell Res. 2021;51:102192. https:\/\/doi.org\/10.1016\/j.scr.2021.102192.","journal-title":"Stem Cell Res"},{"issue":"2","key":"5058_CR190","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41419-018-0310-x","volume":"9","author":"Z Shen","year":"2018","unstructured":"Shen Z, Wang J, Huang Q, Shi Y, Wei Z, Zhang X, et al. Genetic modification to induce CXCR2 overexpression in mesenchymal stem cells enhances treatment benefits in radiation-induced oral mucositis. Cell Death Dis. 2018;9(2):229. https:\/\/doi.org\/10.1038\/s41419-018-0310-x.","journal-title":"Cell Death Dis"},{"key":"5058_CR191","doi-asserted-by":"publisher","first-page":"2457082","DOI":"10.1155\/2019\/2457082","volume":"2019","author":"C Zhang","year":"2019","unstructured":"Zhang C, Zhu Y, Wang J, Hou L, Li W, An H. CXCR4-Overexpressing Umbilical Cord Mesenchymal Stem Cells Enhance Protection against Radiation-Induced Lung Injury. Stem Cells Int. 2019;2019:2457082. https:\/\/doi.org\/10.1155\/2019\/2457082.","journal-title":"Stem Cells Int"},{"key":"5058_CR192","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fsurg.2020.00040","volume":"7","author":"HH Jiang","year":"2020","unstructured":"Jiang HH, Ji LX, Li HY, Song QX, Bano Y, Chen L, et al. Combined Treatment With CCR1-Overexpressing Mesenchymal Stem Cells and CCL7 Enhances Engraftment and Promotes the Recovery of Simulated Birth Injury-Induced Stress Urinary Incontinence in Rats. Front Surg. 2020;7:40. https:\/\/doi.org\/10.3389\/fsurg.2020.00040.","journal-title":"Front Surg"},{"issue":"9","key":"5058_CR193","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1111\/jcmm.13131","volume":"21","author":"X Bai","year":"2017","unstructured":"Bai X, Xi J, Bi Y, Zhao X, Bing W, Meng X, et al. TNF-\u03b1 promotes survival and migration of MSCs under oxidative stress via NF-\u03baB pathway to attenuate intimal hyperplasia in vein grafts. J Cell Mol Med. 2017;21(9):2077\u201391. https:\/\/doi.org\/10.1111\/jcmm.13131.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"5058_CR194","doi-asserted-by":"publisher","first-page":"C80","DOI":"10.1152\/ajpcell.00232.2016","volume":"313","author":"X Li","year":"2017","unstructured":"Li X, He L, Yue Q, Lu J, Kang N, Xu X, et al. MiR-9-5p promotes MSC migration by activating \u03b2-catenin signaling pathway. Am J Physiol Cell Physiol. 2017;313(1):C80\u201393. https:\/\/doi.org\/10.1152\/ajpcell.00232.2016.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"5058_CR195","doi-asserted-by":"publisher","first-page":"10896","DOI":"10.1038\/s41598-021-90383-4","volume":"11","author":"N Nose","year":"2021","unstructured":"Nose N, Nogami S, Koshino K, Chen X, Werner RA, Kashima S, et al. [18F]FDG-labelled stem cell PET imaging in different route of administrations and multiple animal species. Sci Rep. 2021;11(1):10896. https:\/\/doi.org\/10.1038\/s41598-021-90383-4.","journal-title":"Sci Rep"},{"issue":"1","key":"5058_CR196","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.apsb.2018.08.006","volume":"9","author":"X Wang","year":"2019","unstructured":"Wang X, Chen H, Zeng X, Guo W, Jin Y, Wang S, et al. Efficient lung cancer-targeted drug delivery via a nanoparticle\/MSC system. Acta Pharm Sin B. 2019;9(1):167\u201376. https:\/\/doi.org\/10.1016\/j.apsb.2018.08.006.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"5058_CR197","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.1038\/s41598-021-83894-7","volume":"11","author":"CH Masterson","year":"2021","unstructured":"Masterson CH, Tabuchi A, Hogan G, Fitzpatrick G, Kerrigan SW, Jerkic M, et al. Intra-vital imaging of mesenchymal stromal cell kinetics in the pulmonary vasculature during infection. Sci Rep. 2021;11(1):5265. https:\/\/doi.org\/10.1038\/s41598-021-83894-7.","journal-title":"Sci Rep"},{"issue":"1","key":"5058_CR198","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.stem.2009.05.003","volume":"5","author":"RH Lee","year":"2009","unstructured":"Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54\u201363. https:\/\/doi.org\/10.1016\/j.stem.2009.05.003.","journal-title":"Cell Stem Cell"},{"key":"5058_CR199","doi-asserted-by":"publisher","first-page":"30418","DOI":"10.1038\/srep30418","volume":"6","author":"S Kalimuthu","year":"2016","unstructured":"Kalimuthu S, Gangadaran P, Li XJ, Oh JM, Lee HW, Jeong SY, et al. In Vivo therapeutic potential of mesenchymal stem cell-derived extracellular vesicles with optical imaging reporter in tumor mice model. Sci Rep. 2016;6:30418. https:\/\/doi.org\/10.1038\/srep30418.","journal-title":"Sci Rep"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-05058-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05058-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05058-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:47:07Z","timestamp":1781171227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-05058-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":199,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5058"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-05058-6","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors agree to publish their manuscript in Stem Cell Research & Therapy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors affirm that no generative AI technologies were used in the creation or writing of this manuscript. As a retrospective literature review that did not involve direct patient data or intervention, this study was exempt from ethical approval by institutional policy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI and ethics declarations"}},{"value":"A systematic literature search was conducted to identify studies investigating mesenchymal stromal cells (MSCs) for the treatment of systemic lupus erythematosus (SLE). The search was performed across the PubMed, Web of Science, Scopus, and Cochrane Library databases, covering the period from database inception to May 2025. To capture the most recent advances while ensuring a comprehensive historical context, we prioritized publications from the last five years (2020\u20132025), while also including seminal earlier studies that established foundational concepts (e.g., the discovery of MSCs, first reports of HSC transplantation in SLE). The search strategy employed combinations of the following keywords: \u201cMesenchymal Stromal Cells,\u201d \u201cMesenchymal Stem Cells,\u201d \u201cMSCs,\u201d \u201cSystemic Lupus Erythematosus,\u201d \u201cSLE,\u201d \u201cImmunomodulation,\u201d \u201cClinical Trial,\u201d \u201cEfficacy,\u201d \u201cSafety,\u201d \u201cCell Therapy,\u201d and \u201cExtracellular Vesicles.\u201d Additional relevant studies were identified by searching the ClinicalTrials.gov registry and by manually screening the reference lists of included articles. Studies were included if they were (1) original research articles, clinical trials, or review articles focusing on MSC-based therapies for SLE, and (2) written in English. Exclusion criteria were (1) non-English publications, (2) conference abstracts, editorials, or letters without original data, (3) duplicate publications, and (4) studies focusing exclusively on basic mechanisms without any translational or clinical relevance to SLE. Two authors (S.J.D. and S.Y.W.) independently screened titles, abstracts, and full texts, with disagreements resolved through discussion or consultation with a third reviewer (Y.N.C.). For clinical studies, the quality and risk of bias were assessed using appropriate tools (e.g., the Cochrane Risk of Bias tool for randomized controlled trials, and the Joanna Briggs Institute checklist for case series), ensuring a rigorous evaluation of the available evidence. For preclinical studies, methodological quality was assessed based on randomization, blinding, and control groups. For clinical studies, we evaluated potential biases related to selection, performance, and reporting, acknowledging the current scarcity of large-scale randomized controlled trials as a limitation in the field.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Literature search strategy"}},{"value":"It is noted that the acronym \u201cMSC\u201d has historically referred to both \u201cmesenchymal stem cells\u201d and \u201cmesenchymal stromal cells.\u201d In alignment with the 2025 guidelines issued by the International Society for Cellular Therapy, the term \u201cmesenchymal stromal cells\u201d is adopted throughout this review unless otherwise specified.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note on nomenclature"}}],"article-number":"217"}}